News and Announcements
Dimerix’s Latest Research Validating the Relevance of DMX Receptor-HIT Technology Published in Scientific Reports Journal
- Published June 13, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company discovering and developing new therapeutic treatments identified using its proprietary assay technology today announce the publication of important research by Chief Scientific Advisor, Associate Professor Kevin Pfleger and colleagues in the leading peer reviewed journal Scientific Reports.
KEY TAKEAWAYS:
- Using state-of-the-art CRISPR technology, the team at the Harry Perkins Institute of Medical Research led by Associate Professor Pfleger has developed world first tools for studying functional receptor interactions in real time.
- Validate the relevance of the Dimerix Receptor-Heteromer Investigation Technology platform to monitor receptor complexes by labelling and monitoring endogenous receptors with tags for bioluminescence resonance energy transfer.
- The Receptor-HIT technology was used to identify DMX-200, Dimerix’s lead clinical stage drug development program, in Phase II of trials for the treatment of chronic kidney disease.
Associate Professor Pfleger highlighted that “This work has considerable potential for improving drug discovery and profiling, leveraging both Dimerix’s Receptor-HIT platform and the latest advances in genome editing”.
Dimerix’S CEO Kathy Harrison said: “Validation of the power of platform technologies which rely on analysis in vitro can be challenging. This pivotal piece of work has shown that the relevance of the heterodimers (the core premise of Receptor-HIT technology) can be demonstrated in cells in real time under endogenous promoter conditions, as occurs in the physiological setting.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
